AVH Stock Overview
AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.49 |
| 52 Week High | AU$3.23 |
| 52 Week Low | AU$1.28 |
| Beta | 0.92 |
| 1 Month Change | 31.75% |
| 3 Month Change | 67.11% |
| 1 Year Change | -5.68% |
| 3 Year Change | -81.56% |
| 5 Year Change | 94.53% |
| Change since IPO | -95.39% |
Recent News & Updates
Shareholder Returns
| AVH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.6% | -1.4% | 0.6% |
| 1Y | -5.7% | 11.8% | 3.5% |
Return vs Industry: AVH underperformed the Australian Biotechs industry which returned 11.8% over the past year.
Return vs Market: AVH underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| AVH volatility | |
|---|---|
| AVH Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: AVH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AVH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 116 | Jim Corbett | https://www.avitamedical.com |
AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s skin.
AVITA Medical, Inc. Fundamentals Summary
| AVH fundamental statistics | |
|---|---|
| Market Cap | AU$314.94m |
| Earnings (TTM) | -AU$47.14m |
| Revenue (TTM) | AU$37.69m |
8.4x
P/S Ratio-6.7x
P/E RatioIs AVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVH income statement (TTM) | |
|---|---|
| Revenue | US$26.79m |
| Cost of Revenue | US$3.22m |
| Gross Profit | US$23.57m |
| Other Expenses | US$57.08m |
| Earnings | -US$33.50m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 23, 2023
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 87.99% |
| Net Profit Margin | -125.06% |
| Debt/Equity Ratio | 0% |
How did AVH perform over the long term?
See historical performance and comparison